Head to Head Comparison: Inhibrx Biosciences (NASDAQ:INBX) versus Moderna (NASDAQ:MRNA)

Moderna (NASDAQ:MRNA) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Moderna and Inhibrx Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4	15	6	0	2.08
Inhibrx Biosciences	1	2	2	1	2.50

Moderna presently has a consensus price target of $107.10, suggesting a potential downside of 42.39%. Inhibrx Biosciences has a consensus price target of $197.50, suggesting a potential upside of 117.48%. Given Inhibrx Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than Moderna.

Profitability

This table compares Moderna and Inhibrx Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Risk and Volatility

Moderna has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.81, meaning that its stock price is 281% more volatile than the S&P 500.

Institutional & Insider Ownership

75.3% of Moderna shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Moderna and Inhibrx Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94 billion	38.18	-$2.82 billion	($7.99)	-23.27
Inhibrx Biosciences	$1.30 million	1,028.28	-$140.05 million	($8.88)	-10.23

Inhibrx Biosciences has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Inhibrx Biosciences beats Moderna on 10 of the 15 factors compared between the two stocks.

About Moderna

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

About Inhibrx Biosciences

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.